What is GHK-Cu, the copper peptide?

What it is

GHK-Cu is a peptide, a short chain of amino acids (the building blocks of proteins), bound to copper. Its chain has just three amino acids: glycine, histidine and lysine, which give it the letters GHK. Cu is the chemical symbol for copper. It is also called prezatide copper, and cosmetic ingredient lists call it copper tripeptide-1.¹

Loren Pickart and a colleague first reported the peptide in 1973, in the liquid part of human blood. In lab tests it kept normal liver cells alive longer and spurred the growth of liver tumor cells. Pickart and colleagues identified it as glycyl-histidyl-lysine in 1977, and reported in 1980 that it readily binds copper. A 2026 systematic review notes that Pickart held commercial interests in the field for decades. About a third of the GHK-Cu studies it covered from 2005 on list him or a co-author from the same company, which the reviewers said limits the independence of the evidence.^2,3,4,5

Two similar names on ingredient labels are not GHK-Cu. Tripeptide-1 is GHK without copper, and palmitoyl tripeptide-1 is GHK joined to a fatty acid, also without copper, according to the FDA’s substance registry.^6,7

How it works

Most of what is known about how GHK-Cu acts comes from cells and animals. A 1980 lab study found that GHK helped liver tumor cells take up copper. A 1988 study found that GHK-Cu raised collagen production by fibroblasts, the cells that make connective tissue.^8,5,9

Rat studies point both ways. In a 1993 study, GHK-Cu injected into small chambers under rats’ skin increased the collagen and other tissue that built up inside them. In a 2003 study of 24 rats, wounds in skin with a poor blood supply shrank faster with a GHK-Cu gel than with no treatment. Against the same gel without GHK-Cu, the difference showed on only 2 of 13 days.^10,11

In a 2013 study of rats treated with radiation, a GHK-Cu gel did no better than a plain ointment on skin flaps, patches of skin partly cut free and stitched back. In a 2015 study, 72 rats were given knee-joint injections after ligament surgery. Knees were steadier than with salt water at first, but not by the study’s end.^12,13

Claims that GHK resets gene activity rest on lab and computer work. A 2012 study found a pattern of gene activity in lung tissue damaged by emphysema, a lung disease. In a database of lab-grown cells treated with chemicals, GHK shifted gene activity the opposite way. A 2026 review of GHK-Cu’s chemistry called such work a starting point that is often stretched too far. It noted that many of the gene studies used GHK without copper.^14,15

How it is taken

Skin trials have used creams, gels, serums and other skin-care products, but how much GHK-Cu passes through intact skin is uncertain. In a 2015 lab study on human skin samples, almost none crossed intact skin in nine hours, though more did after the skin was pierced with tiny needles (microneedles). A 2010 lab study that tracked only the copper found some crossing skin samples over two days.^{16,17,18,19,20,21,22}

GHK-Cu has also been given by injection. No controlled trial of injecting GHK-Cu on its own is registered on ClinicalTrials.gov, the US trial registry. In published studies from a clinic in Mumbai, India, GHK-Cu was one ingredient of hair-loss mixtures injected into the scalp skin.^{23,24,25,26,27}

What the research in people shows

A 2026 systematic review, which gathers every eligible study by rules set in advance, found 20 studies of GHK-Cu alone for appearance. Eighteen were lab or animal studies, and two were randomized trials in people, which assign people to treatments by chance. Its search ended in March 2026, before a third such trial, on eyebrows, was published. Two older trials tested copper peptide products on chronic wounds against look-alikes with no active ingredient (placebos).^8,20,16,17

Cosmetic claims for GHK-Cu rest on two 2002 studies, of a face cream in 71 women and an eye cream in 41, a 2026 review found. Both reported improvements but appeared only as conference abstracts, never as full papers.^3,15,19

The 2016 wrinkle trial measured one large wrinkle near the eye in each woman. The plain serum lacked both GHK-Cu and its fat-based carrier, so the trial cannot show which made the difference; the authors credited the carrier. The serum’s maker co-funded the study, though the paper says it had no part in the analysis. Its journal is not indexed in MEDLINE, the US National Library of Medicine’s index of selected journals.^19,29

The eyebrow trial was double-blind: neither the participants nor the researchers knew which side got GHK-Cu. It appeared as a conference paper, not in a medical journal. The chemistry review called it the strongest recent controlled result for appearance, but noted that it was small, ran at one center and did not report the chemical form of its GHK-Cu.^20,15

Other hair studies in people combined GHK with other ingredients. A 2026 systematic review of 14 peptide hair-loss trials favored such combinations, a design that cannot show what GHK adds.³⁰

The Mumbai clinic’s 2018 study of 1,000 people had no comparison group. In a 2020 randomized study of 50 men, a mixture did better than platelet-rich plasma, made from a patient’s own blood. A 2022 study gave 20 people with patchy hair loss (alopecia areata) steroid injections plus either a mixture or a placebo. Its published summary reports improvement from the start of treatment and more satisfaction in the mixture group, but no direct comparison of regrowth between the groups. The mixtures also contain growth factors (proteins that signal cells to grow) or plant-made look-alikes, so none of these studies can show what GHK-Cu does alone.^24,25,26,27

A 2025 study in India, not randomized, compared microneedling with and without a copper peptide serum in 40 adults with acne scars over 16 weeks. Microneedling pricks the skin with a roller of tiny needles. The authors concluded that the serum added only limited benefit. The paper also calls the serum a tripeptide-1 product, the name for GHK without copper.^31,6

A company-sponsored randomized, double-blind trial in China plans to enroll 60 healthy adults. Each gets two small round wounds on the upper arm, one treated with a GHK-Cu gel and the other with the same gel without it. Its sponsor, Hudson Biotech, registered eight drug trials at the same hospital in Shenzhen in early 2026, including trials of BPC-157, TB-500 and MOTS-c. The sponsor supplied the record, which does not list the trial as a study of an FDA-regulated drug.^32,46

Side effects and risks

The skin trials were small and short, so uncommon side effects could have been missed. In the 2016 wrinkle trial, 1 of 40 women had a minor skin reaction on both sides of her face: the GHK-Cu side and the related-peptide side. It cleared after she stopped. The eyebrow trial reported no side effects, though it excluded anyone who reacted to a patch test beforehand.^19,20

In the 2025 acne scar study, 8 of the 20 people given a copper peptide serum after microneedling developed darker patches of skin (hyperpigmentation). None of the 20 given microneedling alone did, and the authors reported that the patches lessened after the study ended.³¹

The FDA has said compounded injectable GHK-Cu may provoke immune reactions (immunogenicity), because the peptide can clump together (aggregation) and may contain peptide-related impurities, near-copies of the peptide formed during manufacture. It added that data in people on its safety are limited.³³

The 1973 study found that GHK spurred the growth of liver tumor cells in the lab. The 2026 systematic review found that lab and animal studies consistently showed GHK-Cu promoting the growth of new blood vessels (angiogenesis). The 2013 rat study, though, saw no difference in blood vessels. The chemistry review noted that new vessels can help wounds heal but may be harmful in tumors and some eye diseases.^2,8,12,15

The same review found no formal published studies of how the body absorbs, distributes and clears GHK-Cu. It said any injected product would need testing for sterility, immune reactions, blood vessel effects and how much copper reaches the rest of the body.¹⁵

Any GHK-Cu drug a pharmacy prepares is compounded. The FDA warns that poor compounding practices can leave a drug contaminated or with too much or too little active ingredient, which can lead to serious injury and death.³⁴

FDA status

No drug containing GHK-Cu is FDA-approved, and none appears in Drugs@FDA, the agency’s database of approved drugs. In 1996 the FDA cleared a wound-dressing gel containing GHK-Cu as a medical device, for some of the uses requested. Device clearance is a separate process from drug approval.^35,36,11,37

Cosmetics, other than color additives, need no FDA approval before sale. A product’s intended use, shown by claims on the label, in ads or online, decides whether it is a cosmetic, a drug or both. A product that makes lines less noticeable just by moisturizing is a cosmetic. One intended to remove wrinkles or increase the skin’s production of collagen is a drug or a medical device, even if sold as a cosmetic.^38,37

Compounded drugs are not FDA-approved either: the FDA does not check their safety, effectiveness or quality before they are sold. GHK-Cu has no official quality standard (a US Pharmacopeia monograph) and is in no FDA-approved drug. It is also not on the 503A bulks list, the FDA’s list of extra ingredients that state-licensed pharmacies may compound with under section 503A. The FDA is deciding whether to add it.^34,39,40

Meanwhile, under an interim policy, the FDA lists GHK-Cu, except for injection, in Category 1, substances under evaluation. It does not intend to act against pharmacies that compound with Category 1 substances if they meet the policy’s conditions. The FDA briefly removed GHK-Cu from Category 1 on April 22, 2026, after its nominations were withdrawn. One nominator then said it had meant to withdraw only the injectable form, and the FDA’s May 14 update restored it. It was still there as of November 13, 2026.^39,41,40

Injectable GHK-Cu is not in Category 1, so that policy does not cover it. The FDA had placed it in Category 2, substances that “may present significant safety risks”, citing possible immune reactions and limited data in people. The nomination was later withdrawn, but the FDA’s page still lists those concerns.^40,41,33

The FDA’s Pharmacy Compounding Advisory Committee, a panel of outside experts, will discuss whether to add GHK-Cu to the 503A bulks list. The meeting is planned before the end of February 2027; as of November 13, 2026, the FDA’s page gave no date.^42,40

On October 30, 2026, the FDA’s parent department, Health and Human Services (HHS), announced a draft policy on compounding six peptides under section 503A. HHS says it does not intend to take enforcement action against state-licensed pharmacies and licensed physicians that compound them and meet all its conditions. GHK-Cu is not one of the six peptides the policy names. The draft is not binding.^43,47

Rules in sport

The World Anti-Doping Agency’s 2027 Prohibited List, in force from January 1, 2027, does not name GHK-Cu. But its catch-all section bans, at all times, any drug that no government health regulator has approved as a medicine for people. The 2027 list names peptides as an example.^44,45

What isn’t known

Questions to ask a clinician